TDP43 promotes stemness of breast cancer stem cells through CD44 variant splicing isoforms
Abstract Alternative splicing (AS) is a promising clinical target for cancer treatment at the post-transcriptional level. We previously identified a unique AS profile in triple-negative breast cancer (TNBC), which is regulated by the splicing regulator TAR DNA-binding protein-43 (TDP43), thus indica...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-05-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-022-04867-w |